Bonum Therapeutics, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Bonum Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2026).
SEC Form D · Apr 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2026
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Bonum Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Diane Hollenbaugh | Executive officer | Apr 2026 |
| John Mulligan | Executive officer | Apr 2026 |
| Neela Patel | Executive officer | Apr 2026 |
| Gaurav Aggarwal | Director | Apr 2026 |
| John McKearn | Director | Apr 2026 |
| John Mulligan | Director | Apr 2026 |
| Karl Handelsman | Director | Apr 2026 |
| Mitchell Mutz | Director | Apr 2026 |
| Monique Schiersing | Director | Apr 2026 |
| Nicholas Walrod | Director | Apr 2026 |
| Samuel Bjork | Director | Apr 2026 |
| Samuel Blackman | Director | Apr 2026 |
| John Mulligan | Promoter | Apr 2026 |